Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Hum Immunol ; 67(4-5): 363-73, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16720219

RESUMEN

We previously revealed that one of the human leukocyte antigen-linked susceptibility genes for Takayasu's arteritis (TA) was mapped between TNFA and MICB loci and that -63T allele of NFKBIL1, which is between TNFA and MICB loci, was associated with rheumatoid arthritis (RA) in the Japanese population. We have developed a novel typing method based on reference strand-mediated conformation analysis for the upstream sequence of the NFKBIL1 gene, where -422 (T)8/(T)9, -325 C/G, -263 A/G, and -63 T/A polymorphisms were found. Upon the analysis of the patients with TA (n = 84), those with RA (n = 120), and healthy control subjects (n = 217), five common haplotypes named IKBLp*01 through IKBLp*05 were found in the Japanese population. The frequency of IKBLp*03 was significantly increased in the patient with TA (57.1% vs 35.0%, giving an odds ratio of 2.47). In addition, the frequency of IKBLp*01, but not that of other -63T-bearing alleles, was increased in the patients with RA (73.3% vs 58.1%, giving an odds ratio of 1.99), suggesting that the susceptibility to RA was conferred not by -63T alone but by combination of single nucleotide polymorphisms in the NFKBIL1 promoter. A higher promoter activity associated with IKBLp*03 and a lower activity associated with IKBLp*01 may contribute to the susceptibility to TA and RA, respectively.


Asunto(s)
Artritis Reumatoide/genética , Antígenos de Histocompatibilidad Clase II/genética , Polimorfismo de Nucleótido Simple , Polimorfismo Conformacional Retorcido-Simple , Análisis de Secuencia de ADN/métodos , Arteritis de Takayasu/genética , Proteínas Adaptadoras Transductoras de Señales , Enfermedad Crónica , ADN/química , Frecuencia de los Genes , Predisposición Genética a la Enfermedad , Haplotipos , Humanos , Desequilibrio de Ligamiento , Conformación de Ácido Nucleico , Regiones Promotoras Genéticas , Transcripción Genética
2.
Circ J ; 70(5): 600-4, 2006 May.
Artículo en Inglés | MEDLINE | ID: mdl-16636497

RESUMEN

BACKGROUND: Inflammation and thrombosis are closely related processes, but the association between disease activity and thrombogenicity in Takayasu's arteritis (TA) is poorly understood. To investigate the link between platelet activation and disease activity, flow cytometric analyses of platelet P-selectin and activated GPIIb/IIIa expression were performed in patients with TA. METHODS AND RESULTS: Twenty-two patients with TA, classified into active (Group A, n = 9) and inactive (Group I, n = 13) according to blood-derived inflammatory markers, and 14 healthy age- and gender-matched controls (Group C) were studied. Compared with Group C, the mean fluorescence intensity of P-selectin in response to 0.1-10 micromol/L of ADP was significantly upregulated in Group A, but not in Group I. No differences in platelet GPIIb/IIIa expression in stimulated platelets were seen among the 3 groups. Standard platelet aggregation studies revealed that disease activity did not influence platelet aggregation by ADP. CONCLUSIONS: P-selectin expression, but not activated GPIIb/IIIa, is enhanced in ADP-activated platelets from patients in the inflammatory stage of TA. P-selectin may play a significant role in the inflammatory and thrombotic responses associated with intractable TA, presumably by inducing platelet-leukocyte interactions.


Asunto(s)
Inflamación/etiología , Selectina-P/análisis , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/metabolismo , Arteritis de Takayasu/sangre , Arteritis de Takayasu/patología , Adenosina Difosfato/farmacología , Adulto , Anciano , Estudios de Casos y Controles , Femenino , Citometría de Flujo , Humanos , Persona de Mediana Edad , Activación Plaquetaria/efectos de los fármacos , Agregación Plaquetaria/efectos de los fármacos , Arteritis de Takayasu/complicaciones , Trombosis/etiología
3.
J Nucl Med ; 46(6): 917-22, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15937300

RESUMEN

UNLABELLED: The purpose of this study was to evaluate the ability of (18)F-FDG PET to identify aortitis and to localize and follow disease activity in patients with Takayasu arteritis. The value of using (18)F-FDG PET coregistered with enhanced CT in determining vascular lesion sites and inflammatory activity was assessed. METHODS: Takayasu arteritis was diagnosed according to the predefined criteria. Eleven patients with Takayasu arteritis in the active stage, 3 patients with Takayasu arteritis in the inactive stage, and 6 healthy subjects underwent (18)F-FDG PET coregistered with enhanced CT and the inflammatory vascular lesion was evaluated by using the standardized uptake value (SUV) of (18)F-FDG accumulation as an index. Two patients with active disease were analyzed by sequential (18)F-FDG PET scans during treatment. RESULTS: The (18)F-FDG PET revealed intense (18)F-FDG accumulation (SUV > or = 2.7) in the vasculature of 2 of the 11 cases in the active stage of Takayasu arteritis. The other 9 patients in the active stage revealed weak (18)F-FDG accumulation (2.3 > or = SUV > or = 1.2). No significant (18)F-FDG accumulation was observed in the patients with inactive disease (SUV < or = 1.2) and 6 control healthy subjects (SUV < 1.3). Given the cutoff SUV is 1.3, the sensitivity of (18)F-FDG PET analysis of Takayasu arteritis is 90.9% and the specificity is 88.8%. (18)F-FDG PET coregistered with enhanced CT localized (18)F-FDG accumulation in the aortic wall in the patients with Takayasu arteritis who had weak (18)F-FDG accumulation that could not otherwise be identified anatomically. Finally, (18)F-FDG accumulation resolved with therapy in 2 active cases. The disappearance of (18)F-FDG accumulation did not coincide with the level of general inflammatory markers. CONCLUSION: The (18)F-FDG PET images coregistered with enhanced CT images showed the distribution and inflammatory activity in the aorta, its branches, and the pulmonary artery in patients with active Takayasu arteritis, even those who had weak (18)F-FDG accumulation. The intensity of accumulation decreased in response to therapy.


Asunto(s)
Aorta , Aortitis/diagnóstico por imagen , Fluorodesoxiglucosa F18 , Radiofármacos , Arteritis de Takayasu/diagnóstico por imagen , Adolescente , Adulto , Aorta/diagnóstico por imagen , Aortitis/etiología , Aortografía , Femenino , Radioisótopos de Flúor , Humanos , Masculino , Persona de Mediana Edad , Tomografía de Emisión de Positrones , Arteritis de Takayasu/complicaciones , Tomografía Computarizada de Emisión
4.
Hepatogastroenterology ; 50(54): 1978-82, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-14696447

RESUMEN

BACKGROUND/AIMS: To investigate the effect of parasympathetic blockade on the hepatic circulation, a study was performed in healthy men because the precise knowledge of factors to affect the hepatic circulation is required for the evaluation of liver diseases. METHODOLOGY: Doppler measurements of the hepatic venous and portal venous flow were obtained with measurements of cardiac function before and after the administration of atropine sulfate, 0.02 mg/kg. RESULTS: Parasympathetic blockade increased heart rate and cardiac output and changed diastolic right ventricular filling pattern. However, portal venous flow remained unchanged. Hepatic venous flow was triphasic at rest in 15 of the 20 subjects (75%). The amplitude of the oscillation of hepatic venous flow velocity was significantly reduced in association with an increase in heart rate and the hepatic venous flow pattern was significantly influenced by parasympathetic blockade in accordance with a change in right ventricular filling pattern. CONCLUSIONS: The autoregulation of portal venous flow was suggested to exist and that the influences of parasympathetic activity and/or heart rate affected hepatic venous flow pattern.


Asunto(s)
Atropina/farmacología , Procesamiento de Imagen Asistido por Computador , Circulación Hepática/efectos de los fármacos , Parasimpatolíticos/farmacología , Sistema Porta/inervación , Vena Porta/inervación , Ultrasonografía Doppler en Color/efectos de los fármacos , Ultrasonografía Doppler Dúplex/efectos de los fármacos , Adolescente , Adulto , Anciano , Velocidad del Flujo Sanguíneo/efectos de los fármacos , Hemodinámica/efectos de los fármacos , Humanos , Inyecciones Intravenosas , Masculino , Persona de Mediana Edad , Sistema Porta/diagnóstico por imagen , Sistema Porta/efectos de los fármacos , Vena Porta/diagnóstico por imagen , Vena Porta/efectos de los fármacos , Flujo Pulsátil/efectos de los fármacos , Flujo Sanguíneo Regional/efectos de los fármacos
5.
Arthritis Rheum ; 49(4): 594-8, 2003 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-12910568

RESUMEN

OBJECTIVE: To elucidate epidemiologic and clinical manifestations of Japanese patients with giant cell arteritis (GCA), the first nationwide survey for GCA was conducted in 1998 in Japan. METHODS: The first questionnaire on GCA for patients treated in 1997 was sent to 10,717 medical departments in Japan. A total of 177 patients were reported. Among the 177 patients, 66 GCA patients with detailed clinical and epidemiologic features on second survey were analyzed. RESULTS: Prevalence in patients 50 years of age and older in 1997 was 1.47 per 100,000 population in Japan. The average age at onset was 71.5 years old. The male:female ratio was 1:1.7. The association with permanent and complete visual loss (6.5%), jaw claudication (15.2%), and polymyalgia rheumatica (PMR) (30.3%) were low in frequency compared with those reported from other countries. All patients were treated with corticosteroids. Only 3 (4.5%) patients were reported as deceased due to other causes. CONCLUSION: The prevalence of GCA in Japan was revealed to be extremely low compared with other countries. Clinical findings of permanent and complete visual loss, jaw claudication, and PMR were infrequent among Japanese patients with GCA.


Asunto(s)
Arteritis de Células Gigantes/epidemiología , Anciano , Anciano de 80 o más Años , Angiografía , Biopsia , Femenino , Arteritis de Células Gigantes/diagnóstico , Arteritis de Células Gigantes/patología , Humanos , Japón/epidemiología , Masculino , Persona de Mediana Edad , Prevalencia
7.
J Cardiovasc Pharmacol ; 40(4): 571-6, 2002 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-12352319

RESUMEN

This study investigated whether a circadian variation is present in the sensitivity of platelets to nitric oxide (NO) and, if so, if long-term smoking modifies it. Blood samples were taken at 0:00, 6:00, 9:00, 12:00, and 18:00 from 14 nonsmokers and 10 smokers. Dose-response curves for platelet aggregation by collagen were constructed in both the presence and absence of 1.0 micro M of NOR-3, a NO donor. The antiaggregation properties of NOR-3 were quantified by the half maximal concentration (EC50) ratio in the presence of NOR-3 to that in its absence. Platelet aggregation showed a monophasic circadian rhythm, with the lowest levels at 6:00 and the highest at 18:00 in both groups. However, there was a significant (p < 0.01) upward shifting of platelet aggregation in the smokers. A circadian variation in sensitivity to NOR-3 also was demonstrated in the nonsmokers. The sensitivity was lowest at 6:00 (1.68 +/- 0.19), increased significantly at 9:00 (2.58 +/- 0.26; p < 0.01), and remained high at 12:00 (2.47 +/- 0.21; p < 0.05). In smokers, however, a circadian variation in platelet sensitivity to NOR-3 was not found. Furthermore, the sensitivity was significantly lower at 9:00 and 12:00 in smokers (1.94 +/- 0.26 and 1.76 +/- 0.13, respectively; p < 0.05 for both) than in nonsmokers. Thus, long-term smoking impairs the normal morning increase in platelet sensitivity to NO, making platelets in smokers more thrombogenic during the hazardous hours.


Asunto(s)
Ritmo Circadiano/fisiología , Óxido Nítrico/metabolismo , Agregación Plaquetaria/fisiología , Fumar/sangre , Adulto , Análisis de Varianza , Estudios Transversales , Epinefrina/sangre , Humanos , Masculino , Persona de Mediana Edad , Donantes de Óxido Nítrico/farmacología , Norepinefrina/sangre , Agregación Plaquetaria/efectos de los fármacos
8.
Atherosclerosis ; 161(1): 225-32, 2002 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11882336

RESUMEN

Activation of platelets by acute vigorous exercise has been demonstrated by various parameters, including an increase in agonist-induced platelet [Ca2+]i levels. However, direct evidence is lacking regarding how acute exercise affects platelet-derived NO. Twenty-three healthy male non-smokers (21-59 years) underwent a symptom-limited treadmill exercise test. Washed platelets were prepared from blood samples obtained before and immediately after exercise. All subjects completed at least Bruce stage 2 and were each negative for ischemia. With a low dose (2 microg/ml) of collagen, NO release from washed platelets, detected by the NO-selective microelectrode, was significantly increased after exercise (pmols/10(8) platelets, before: 0.64+/-0.11, after: 1.03+/-0.18; P<0.005) without changes in aggregation ability. This enhanced NO release was accompanied by increased platelet [Ca2+]i levels (before: 232+/-25, after: 296+/-37; P<0.01). With a high dose (5 or 10 microg/ml) of collagen, NO release and aggregation were both modestly, but significantly, enhanced after exercise. The exercise-induced enhancement of platelet NO release in response to collagen was also suggested by increase in platelet cyclic guanosine monophosphate accumulation and augmenting effect of N(G)-monomethyl-L-arginine on platelet aggregation. In summary, acute strenuous exercise primes enhanced NO release and may play a protective role against exercise-induced activation of platelets in normal subjects.


Asunto(s)
Plaquetas/metabolismo , Ejercicio Físico/fisiología , Óxido Nítrico/sangre , Adulto , Plaquetas/efectos de los fármacos , Calcio/sangre , Colágeno/farmacología , GMP Cíclico/sangre , Inhibidores Enzimáticos/farmacología , Humanos , Masculino , Persona de Mediana Edad , Agregación Plaquetaria/efectos de los fármacos , Valores de Referencia , omega-N-Metilarginina/farmacología
9.
Atherosclerosis ; 161(2): 281-91, 2002 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11888510

RESUMEN

Vascular endothelial cell death contributes to the progression of atherosclerotic lesion, and several transcriptional regulators are involved in the process. Activating transcription factor 3/liver regenerating factor-1 (ATF3/LRF-1), a stress-inducible transcriptional repressor, was shown to be highly expressed in vascular endothelial cells and macrophages of human atherosclerotic lesions by immunohistological assay. The expression was colocalized in these cells which were positive for TdT-mediated dUTP nick-end labeling (TUNEL) and annexin V. Treatment of human umbilical vein endothelial cells (HUVECs) by tumor necrosis factor (TNF)-alpha, oxidized low density lipoprotein (oxLDL), and lysophosphatidylcholine (LPC) rapidly induced ATF3/LRF-1, which showed an increased DNA binding to the consensus ATF/CRE sequence by supershift of gel shift assay. Flow cytometry analysis and immunostaining analysis with TUNEL assay showed that ATF3/LRF-1 was highly expressed in cell death induced by these agents. Moreover, antisense ATF3/LRF-1 cDNA partly suppressed the cell death induced by TNF-alpha, oxLDL, and LPC. From these results, it is indicated that ATF3/LRF-1 is one of the immediate early response genes in vascular endothelial cells in response to atherogenic stimuli, and may play a role in the endothelial cell death associated with atherogenesis.


Asunto(s)
Arteriosclerosis/etiología , Arteriosclerosis/patología , Muerte Celular/efectos de los fármacos , Proteínas de Unión al ADN/metabolismo , Endotelio Vascular/metabolismo , Factores de Transcripción/metabolismo , Factor de Transcripción Activador 3 , Secuencia de Bases , Northern Blotting , Western Blotting , Muerte Celular/fisiología , Células Cultivadas , Proteínas de Unión al ADN/efectos de los fármacos , Endotelio Vascular/citología , Citometría de Flujo , Regulación de la Expresión Génica , Humanos , Inmunohistoquímica , Lipoproteínas LDL/farmacología , Lisofosfatidilcolinas/farmacología , Datos de Secuencia Molecular , Reacción en Cadena de la Polimerasa , Probabilidad , Factores de Transcripción/efectos de los fármacos , Factor de Necrosis Tumoral alfa/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...